Most cancer breakthroughs are measured in charts. This one is
visible under a microscope.

Time-lapse footage from a recent clinical study shows immune cells
attacking and eliminating cancer cells.

These are NATURAL KILLER (NK) CELLS, the part of the immune system
tasked with identifying and destroying abnormal cells before tumors
spread.

But in advanced cancers, they can become depleted. When they do,
tumors regain control.

GT BIOPHARMA (NASDAQ: GTBP)
[[link removed]]
is building its platform around amplifying these cells.

Its TriKE® platform is designed to keep NK cells active longer -
fueling them to stay locked onto cancer cells.

In side-by-side comparisons, the effect was clear:

NK cells alone slowed tumors. But when combined with the company's
TriKE® technology, cancer cells declined sharply.

Early human data showed up to a 63.7% REDUCTION IN CANCER burden.

Now the company's next-generation version, showing potential for
10-40× GREATER POTENCY, has cleared an important FDA milestone.

Watch the microscopic footage and learn more
about GT Biopharma's next catalyst.

MARKET TACTIC





The message was provided by a sponsor and does not reflect the
opinions of Media DC

Media DC
1152 15th Street NW Suite 200
Washington, DC xxxxxx




©2026 , Media DC All Rights Reserved

Unsubscribe [[link removed]]